

N-HETEROCYCLIC CARBENE METALLACYCLE CATALYSTS AND METHODS

Field of the Invention

The present invention relates to N-heterocyclic carbene-ligated metallacycle
5 catalysts and precatalysts, and related methods.

Background of the Invention

Transition metal-catalyzed cross-coupling reactions are useful in a wide range of
chemical transformations that have application in pharmaceuticals and materials
10 chemistry. The transition metal catalyst plays a key role in the catalytic cycle. For
example, transition metals such as Pd may be ligated with suitable spectator ligands that
stabilize the metal center and impart the reactivity patterns required for catalytic
performance. Tertiary phosphines are among the most widely used precatalyst ligands
for cross-coupling reactions. One of the most widely-used Pd-phosphine catalyst
15 systems today is based on triphenylphosphine (PPh₃). However, such catalyst systems
often display moderate reactivity and substrate scope. In some cases, the catalyst or
precatalyst system, such as [Pd(PPh₃)₄], exhibits a short shelf life and readily
decomposes upon storage. Other phosphine ligands have been developed, but many
require multi-step syntheses and, thus, are often high in cost. Moreover, a number of
20 phosphines are toxic, air-sensitive and even pyrophoric.

As an alternative to phosphine ligands, N-heterocyclic carbenes (NHCs) have
been shown to impart greater stability and increased catalytic activity in transition metal-
mediated homogeneous catalysis, relative to phosphines. NHCs have stronger sigma-
donating properties relative to phosphine ligands, resulting in stronger bonds formed
25 with the transition metal center. NHC ligands based on 1,3-diarylimidazol-2-ylidenes
and their 4,5-dihydro analogs are often used with a Pd metal center. NHCs are typically
highly air-sensitive and moisture-sensitive, and metal complexes comprising NHCs are
often prepared *in situ* by deprotonation of the corresponding (4,5-dihydro)imidazolium
salts. For example, some catalytic systems may involve the separate addition of various
30 components of the catalytically active species (e.g., metal source, salts of carbene
ligands, etc.) for the *in situ* formation of the catalytically active species. However, while
such catalyst systems have been shown to be useful, in many cases it may be difficult to


control the amount and/or chemical composition of the catalytically active species formed.

Accordingly, improved methods are needed.

5

Summary of the Invention

The present invention provides methods for synthesizing a transition metal-containing precatalyst comprising reacting at least three components all contained together in a single reaction chamber to form a transition metal-containing precatalyst having one of the following structures,




wherein M is Pd, Pt, or Ru; each R¹⁻⁸ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁸ are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a heteroatom; C is alkyl or aryl; D is a heteroatom; X¹ is halide, sulfonate, or carboxylate; X² is a neutral ligand; Y is a counterion; is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof; is a single bond or double bond; and n is an integer between 1 and 3.

15

The present invention also relates to compositions of matter comprising a compound having one of the following structures,


20




wherein M is Pd, Pt, or Ru; each R¹⁻⁸ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁸ are joined to form a cycloalkyl, cycloheteroalkyl,

aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a heteroatom; C is alkyl or aryl ; D is a heteroatom; X^1 is halide, sulfonate, or carboxylate; X^2 is a neutral ligand; Y is a counterion; $\curvearrowright$ is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof; $\equiv$ is a single bond or double bond; and n is an integer

5 between 1 and 3; wherein the compound does not have the following structure,




The present invention also relates to compositions of matter comprising a compound having the following structure,



wherein $\equiv$ is a single bond or double bond.

The present invention also relates to compositions of matter comprising a compound having the following structure,



wherein $\equiv$ is a single bond or double bond.

5

Brief Description of the Drawings

FIG. 1A shows the one-pot synthesis of precatalysts, according to one embodiment of the invention.

FIG. 1B shows the one-pot synthesis of a precatalyst comprising an imidazolium carbene ligand, using a Pd salt in acetonitrile, according to one embodiment of the invention.

FIG. 2 shows a proposed mechanism for activation of a precatalyst of the present invention to form a catalytically active species, according to one embodiment of the invention.

FIG. 3A shows a general synthesis of saturated N-heterocyclic carbene ligand precursors.

FIG. 3B shows the synthesis of N-heterocyclic carbene ligand precursors, according to some embodiments of the invention.

FIG. 3C shows the synthesis of N-heterocyclic carbene ligand precursors, according to some embodiments of the invention.

FIGS. 4A-J show the syntheses of various precatalysts, according to some embodiments of the invention.

FIG. 5 shows general anion exchange reactions of precatalysts according to some embodiments of the invention.

FIG. 6 shows a ligand exchange reaction to produce (a) IPr-Pd(dmba)OAc and (b) IPr-Pd(dmba)OCOCF₃.

FIG. 7 shows a Suzuki-Miyaura cross-coupling between 2-chloro-1,3-xylene and 1-naphthylboronic acid using (a) a weak base and (b) a strong base, (c) a Buchwald-Hartwig amination of 2-chloro-1,3-xylene with 2,6-diisopropylaniline, and (d) a Heck-Mizoroki reaction between 4-bromo-2,6-dimethylaniline and tert-butyl acrylate.

FIG. 8 shows a library of palladium precatalysts, according to some embodiments of the invention.

FIG. 9 shows examples of known NHC-ligated palladacycles.

Detailed Description

The present invention generally relates to materials and methods for catalytic
5 reactions, including transition metal-catalyzed cross-coupling reactions.

Materials and methods of the present invention may be useful in various metal-catalyzed processes, such as cross-coupling of compounds to form carbon-carbon bonds and/or carbon-heteroatom bonds. In some cases, materials of the invention advantageously may be synthesized in one synthetic step without the need for isolation
10 of intermediate compounds. The materials may be stable metal complexes that do not require special handling or processing conditions, such as the exclusion of air, water, and the like. Also, materials of the invention may be synthesized from inexpensive and readily available starting materials, under relatively mild reaction conditions and in high yield. Such materials and methods may be useful in the production of fine chemicals,
15 advanced materials, and specialty polymers.


In some embodiments, the present invention provides stable (e.g., isolable) metal complexes comprising a carbene ligand, such as an N-heterocyclic carbene ligand. The metal complex may further comprise additional ligands, including neutral ligands and charged ligands, which may enhance performance of the catalyst. In some cases, the
20 metal complexes may act as catalysts (e.g., in cross-coupling reactions) or may be precatalysts that are readily activated to catalyze cross-coupling reactions. As used herein, a “precatalyst” may refer to a chemical species which, upon activation, may produce an active catalyst species in a reaction. For example, a metal complex may comprise a ligand which, upon activation, dissociates from the metal complex to
25 generate the catalytically active species. In some cases, the precatalyst may be isolated as a stable compound. As used herein, the term “catalyst” includes active forms of the catalyst participating in the reaction as well as catalyst precursors (e.g., precatalysts) that may be converted *in situ* into the active form of the catalyst. In some embodiments, catalysts of the invention may be advantageous in that the chemical composition,
30 amount, and/or release of the catalytically active species may be controlled.

In some embodiments, a metal complex of the invention may comprise an N-heterocyclic carbene ligand coordinated to a catalytic metal center and a bidentate ligand that, when bound to the metal center, forms a metallacycle that may aid in stabilizing the

metal complex. Upon exposure of the metal complex to an activating agent, the bidentate ligand may be converted to a species which may dissociate from the metal center, generating the catalytically active metal species. As shown in the illustrative embodiment shown in FIG. 2, compound **10** comprising an N-heterocyclic carbene ligand (11) and a bidentate ligand may undergo ligand exchange with activating agent (12) to produce compound **20**. A bond between activating agent **12** and the bidentate ligand may be formed via reductive elimination to produce compound **30**, which may then undergo ligand disassociation to afford product **40** and the active catalyst **50**. In some embodiments, the activating agent may be a nucleophile. In an illustrative embodiment, the activating agent may be a hydride generated in situ from a component of the reaction mixture capable of hydride transfer to the metal center (e.g., Pd). The activating agent can be introduced into the mixture either separately or in combination with (e.g., premixed with) the precatalyst. Such activating agents may include, but are not limited to, formate salts, organometallic derivatives, NaBH₄ or iBu₂AlH or LiAlH₄ and compounds derived thereof.

Catalysts of the invention may be useful in transition metal-catalyzed cross-coupling methodologies, including the Suzuki-Miyaura, Heck-Mizoroki, Negishi, Stille, Kumada-Tamao-Corriu, and Sonogashira cross-coupling reactions, and the like. The catalysts may comprise a transition metal center, such as palladium, platinum, or ruthenium, and an N-heterocyclic carbene ligand, which may serve to modulate catalyst performance, as known to those of ordinary skill in the art.

In some embodiments, the present invention provides transition metal complexes suitable for use in such cross-coupling reactions. The present invention provides compositions of matter comprising compounds having one of the following structures,



wherein M is Pd, Pt, or Ru; each R¹⁻⁸ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁸ are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a

heteroatom; C is alkyl or aryl ; D is a heteroatom; X^1 is a halide, sulfonate, or carboxylate; X^2 is a neutral ligand; Y is a counterion;  an is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof; --- is a single bond or double bond; and n is an integer between 1 and 3; wherein the compound does not have any of the structures shown in FIG. 9. In some cases, Y is a non-coordinating counterion, such as tetrafluoroborate, hexafluorophosphate or tetraarylborate).


In some cases, each R^{1-8} is independently hydrogen, alkyl, cycloalkyl, alkoxy, amino, aryl, heteroaryl, or substituted derivatives thereof; A is carbon, nitrogen, phosphorus, oxygen, or sulfur; B is nitrogen, phosphorus, oxygen, or sulfur; D is nitrogen, phosphorus, arsenic, antimony, oxygen, sulfur, selenium, or tellurium; and n is an integer between 1 and 3.

For example, in some embodiments, A and B are nitrogen; D is nitrogen, phosphorus, or sulfur; R^1 and R^2 are aromatic rings optionally substituted with methyl, ethyl, isopropyl, t-butyl, methoxy, isopropoxy, trifluoromethyl, or phenyl; R^3 and R^4 are phenyl, t-butyl, or are joined together to form a six-membered ring; R^5 and R^6 are hydrogen, t-butyl, methoxy, trifluoromethyl, or are joined together to form an aryl ring; R^7 and R^8 are methyl, isopropyl, t-butyl, phenyl, phenoxy, hydroxyl, R^7 and R^8 are joined together to form a ring; or at least one of R^7 and R^8 is joined to a portion of  to form a ring.


In one set of embodiments, M is Pd, R^1 and R^2 are aromatic rings substituted with ethyl, methyl, isopropyl, tertiary butyl, or combinations thereof, A and B are nitrogen, and D is nitrogen or phosphorus. In some cases, R^1 and R^2 are aromatic rings substituted at the *ortho* positions relative to A and/or B.

In one set of embodiments, the compound is a salt comprising the metal complex and a counterion (e.g., "Y"). The counterion Y may be a weak or non-nucleophilic stabilizing ion, such that activation of a precatalyst may be enhanced and/or undesired side reactions may be reduced. In some cases, the counterion is a non-coordinating ion, wherein substitution of the counterion with a different group may occur rapidly and/or with ease, to generate a catalytically active species. For example, the counterion may be BF_4 , PF_6 , or Ar_4B , wherein Ar is aryl. When the compound is a salt, the metal complex may further comprise a neutral ligand to occupy a vacant coordination site. For example, the neutral ligand may be a nitrile (e.g., acetonitrile), ether (e.g., tetrahydrofuran), or alcohol (e.g., methanol). The catalyst complex may include additional ligands, such as halides, carboxylates, and the like, as required to obtain a stable complex.

In one embodiment, the compound has the following structure,




In one embodiment, the compound has the following structure,




5


In one embodiment, the compound has the following structure,



In one embodiment, the compound has the following structure,




In one embodiment, the compound has the following structure,




10


In one embodiment, the compound has the following structure,




In one embodiment, the compound has the following structure,




In one embodiment, the compound has the following structure,



5 In one embodiment, the compound has the following structure,




In one embodiment, the compound has the following structure,



10 In some embodiments, the transition metal-containing precatalyst is stable in the presence of oxygen. In some embodiments, the transition metal-containing precatalyst is stable in the presence of water.

The present invention also provides methods for synthesizing transition metal-containing catalysts and/or precatalysts as described herein. In some embodiments, the method comprises reacting at least three components all contained together in a single
15 reaction chamber to form a transition metal-containing precatalyst having one of the following structures,




wherein M is Pd, Pt, or Ru; each R¹⁻⁸ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁸ are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a heteroatom; C is alkyl or aryl; D is a heteroatom; X¹ is halide or carboxylate; X² is a neutral ligand; Y is a counterion;  is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof; --- is a single bond or double bond; and n is an integer between 1 and 3.


- One component of the reaction may be a metal source comprising a metal atom that, upon reaction, may form the metal center of the catalyst. For example, the metal source may comprise salts or coordination compounds of palladium, platinum, or ruthenium. Another component of the reaction may be an N-heterocyclic carbene ligand precursor, such as an imidazolium salt, for example. As used herein, an “N-heterocyclic carbene ligand precursor” refers to a chemical moiety containing a species that may be reacted to form an N-heterocyclic carbene ligand that coordinates the metal center.
- Another component of the reaction may be a bidentate ligand, as described herein. The method may further comprise the addition of other reagents, such as a base, inorganic salt, neutral ligand, and/or solvent, to facilitate the reaction. In some cases, the reagent may form a bond with the metal complex. For example, a neutral ligand may be added to the reaction mixture, wherein the neutral ligand coordinates the metal center. In some cases, the reagent may not form a bond with the metal complex, but serves to otherwise promote the formation of the metal complex.

In one embodiment, at least one of the three components is a palladium-containing compound. The palladium-containing may be PdCl₂ or (CH₃CN)₂PdCl₂, for example.


In some embodiments, at least one of the three components is an N-heterocyclic carbene ligand precursor. The N-heterocyclic carbene ligand precursor may have the structure,



In one embodiment, the N-heterocyclic carbene ligand precursor has the structure,




In one embodiment, the N-heterocyclic carbene ligand precursor has the structure,




wherein --- is a single bond or double bond. In some cases, --- is a single bond. In some cases, --- is a double bond.

In one embodiment, the N-heterocyclic carbene ligand precursor has the structure,



wherein --- is a single bond or double bond. In some cases, --- is a single bond. In some cases, --- is a double bond.


In some embodiments, at least one of the three components is a compound having the structure,



wherein each R^{5-8} is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R^{5-8} are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; C is alkyl or aryl; D is a heteroatom; X is halide or carboxylate; --- is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof.

In some embodiments, the palladium-containing compound, the N-heterocyclic carbene and the ligand are not joined by a bond prior to the reacting step.

In some embodiments, the method is represented by Scheme 1,



Scheme 1

In some cases, methods of the invention may involve a “one pot” synthesis. That is, the present invention may involve an (at least) three component, one-pot synthesis of

5 N-heterocyclic metallacycle catalysts. The term “one-pot” reaction is known in the art and refers to a chemical reaction which can produce a product in one step which may otherwise have required a multiple-step synthesis, and/or a chemical reaction comprising a series of steps that may be performed in a single reaction vessel. One-pot procedures may eliminate the need for isolation (e.g., purification) of intermediates and additional

10 synthetic steps while reducing the production of waste materials (e.g., solvents, impurities). Additionally, the time and cost required to synthesize such compounds may be reduced. FIG. 1A shows a “one-pot” synthesis of precatalysts, according to one embodiment of the invention.

In one embodiment, the “one pot” synthesis may comprise the simultaneous

15 addition of at least some components of the reaction to a single reaction chamber. In one embodiment, the “one pot” synthesis may comprise sequential addition of various reagents to a single reaction chamber.

Methods of the invention may allow for the facile synthesis of libraries of precatalysts. That is, for example, the methods described herein may allow for the

20 combinatorial access to a wide variety of precatalyst frameworks, which may be quickly screened for use as catalysts in cross-coupling reactions. FIG. 8 shows one embodiment of a library of precatalysts that may be synthesized according to the methods described herein. The availability of a wide range of precatalysts may enable the discovery of optimal conditions for a particular cross-coupling reaction, or class of cross-coupling

25 reactions.

As used herein, the term “nucleophile” or “nucleophilic species” is given its ordinary meaning in the art and refers to a chemical moiety having a reactive pair of

electrons. Examples of nucleophiles include uncharged compounds such as water, amines, mercaptans and alcohols, and charged moieties such as hydrides, alkoxides, thiolates, carbanions, and a variety of organic and inorganic anions. Organometallic reagents such as organocuprates, organozincs, organolithiums, Grignard reagents, enolates, acetylides, and the like may, under appropriate reaction conditions, may also be suitable nucleophiles. In some cases, the activation agent is a nucleophile such as a hydride, alkoxide, amine, or organometallic reagent. Those of ordinary skill in the art would be capable of selecting an appropriate nucleophile for use as an activating agent.

In some embodiments, metal complexes of the invention may comprise a bidentate ligand which, when bound to a metal center, forms a metallacycle structure with the metal center. Bidentate ligands suitable for use in the present invention include species which have at least two sites capable of binding to a metal center. For example, the bidentate ligand may comprise at least two heteroatoms that coordinate the metal center, or a heteroatom and an anionic carbon atom that coordinate the metal center. The bidentate ligand may also be capable of stabilizing a metal complex comprising an N-heterocyclic carbene ligand. In some embodiments, the bidentate ligand may be chiral and may be provided as a racemic mixture or a purified stereoisomer. Examples of bidentate ligands suitable for use in the invention include, but are not limited to, aryl groups (e.g., bis-aryl, heteroaryl-substituted aryl), heteroaryl groups, alkyl and aryl derivatives of moieties such as amines, phosphines, phosphites, phosphates, imines, oximes, ethers, hybrids thereof, substituted derivatives thereof, and the like.

In some embodiments, the bidentate ligand is an aryl group substituted with an amine or alkylamine, wherein coordination to the metal center occurs via a carbon of the aryl group and the nitrogen of the amine group.

Additional ligands may coordinate to the metal center, including neutral ligands and/or charged ligands. Neutral ligands include ligands which may coordinate the metal center but do not alter the oxidation state of the metal center. For example, solvent molecules such as acetonitrile may be neutral ligands. Charged ligands include ligands which may coordinate the metal center and may alter the oxidation state of the metal center. Examples of charged ligands include halides, carboxylates, and the like.

Transition metals suitable for use in the present invention include those which are capable of undergoing oxidative-addition and/or reductive elimination reactions, or other processes associated with cross-coupling reactions. The transition metal may preferably

be capable of mediating a cross-coupling reaction to form, for example, carbon-carbon bonds and/or carbon-heteroatom bonds. Transition metals may include transition metals (e.g., Groups 3-12), lanthanides, and actinides. In some cases, transition metals from Groups 8-12 are preferred. In some cases, transition metals from Groups 8-10 are preferred. For example, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, palladium, and platinum may be preferred. In some embodiments, palladium and ruthenium are preferred.

Various metal-containing compounds may be suitable for use in methods of the invention. In some cases, the metal-containing compound is a palladium-containing compound. The palladium-containing compound may be PdCl_2 , $\text{Pd}(\text{OAc})_2$, $(\text{CH}_3\text{CN})_2\text{PdCl}_2$, $[\text{Pd}(\text{PPh}_3)_4]$, or the like.

In some cases, materials of the present invention may comprise N-heterocyclic carbenes, which, without wishing to be bound by theory, may be used as supporting ligands in catalytic processes to enhance the rate and efficiency of the catalytic process and to reduce undesirable side reactions. Examples of N-heterocyclic carbenes include imidazol-2-ylidenes, thiazol-2-ylidenes, dihydroimidazol-2-ylidenes, dihydrothiazol-2-ylidenes, cyclic diaminocarbenes, and other heteroamino carbenes comprising one or more heteroatoms. In some cases, N-heterocyclic carbenes comprising more than two heteroatoms may also be used (e.g., triazol-5-ylidenes).

In some instances, methods of the invention may require additional reagents to promote reactivity of components of the reaction (e.g., metal source, N-heterocyclic carbene salt, bidentate ligand). In particular, it may be advantageous to include a suitable base. For example, the reaction may comprise the insertion (e.g., oxidative addition) of the metal center into a carbon-hydrogen of the bidentate ligand, and the base may serve to deprotonate (e.g., remove the hydrogen) the metal center. The base may also serve to neutralize any acidic species that may be formed during the reaction. In general, a variety of bases may be used in practice of the present invention, such as organic bases and inorganic bases. The base may optionally be sterically hindered to discourage metal coordination of the base in those circumstances where such coordination is possible, i.e., alkali metal alkoxides. Examples of bases include, but are not limited to, alkoxides, alkali metal amides, tertiary amines (e.g. triethylamine, trimethylamine, $\text{Et}(i\text{-Pr})_2\text{N}$, Cy_2MeN , 4-(dimethylamino)pyridine (DMAP), 2,6-lutidine, N-methylpyrrolidine, quinuclidine, and the like), 1,5-diazabicyclo[4.3.0]non-5-ene

(DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU), alkali and alkaline earth carbonates (e.g., Li_2CO_3 , Na_2CO_3 , K_2CO_3 , Cs_2CO_3 , alkali and alkaline earth bicarbonates, alkali and alkaline earth hydroxides, alkali and alkaline earth hydrides, and the like. In some cases, the base is an inorganic base, such as K_2CO_3 .

5 Some embodiments of the invention may also require addition of an inorganic salt, including metal halides, metal carbonates and bicarbonates, metal nitrates, metal sulfates, and the like.

 In some cases, the solvent may be a polar solvent. Examples of polar solvents include, but are not limited to acetonitrile, DMF, THF, ethylene glycol dimethyl ether
10 (DME), DMSO, acetone, methanol, ethanol, isopropanol, n-propanol, t-butanol or 2-methoxyethyl ether, and the like. In a particular embodiment, the solvent is acetonitrile.

 As used herein, the term "reacting" refers to the forming of a bond between two or more components to produce a stable, isolable compound. For example, a first component and a second component may react to form one reaction product comprising
15 the first component and the second component joined by a covalent bond. That is, the term "reacting" does not refer to the interaction of solvents, catalysts, bases, ligands, or other materials which may serve to promote the occurrence of the reaction with the component(s). A "stable compound" or "isolable compound" refers to an isolated reaction product and does not refer to unstable intermediates or transition states.

20 While several embodiments of the present invention have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the present invention. More generally,
25 those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present invention is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine
30 experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the invention may be practiced otherwise than as specifically

described and claimed. The present invention is directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not
5 mutually inconsistent, is included within the scope of the present invention.

The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in the claims, should
10 be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. Thus, as a non-limiting example, a reference to
15 “A and/or B,” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

As used herein in the specification and in the claims, “or” should be understood
20 to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will
25 refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.

30 As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the

list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

EXAMPLES

Example 1

FIG. 3A shows a schematic synthesis of compound ITbp-HCl, which was synthesized according to the following method. To a solution of 2-*tert*-butylaniline (20.4 mL, 19.6 g, 131 mmol) in mixture of methanol (50 mL) and water (5 mL), a glyoxal solution (40% in water; 7.5 mL, 9.43 g, 65 mmol) was added, and the mixture stirred over 1.5 h. The yellow crystalline mass of the diazabutadiene intermediate was filtered off, dried with a stream of air, and then vacuum-dried over P₂O₅. The diazabutadiene was obtained as yellow powder (19.91 g, 96%) and used directly for the next step.

To a solution of the diazabutadiene (6.41 g, 20 mmol) in THF (40 mL), chloromethyl ethyl ether (2.0 mL, 2.08 g, 22 mmol) and water (0.4 mL) were added in succession and the mixture was stirred at 40°C over 18h. The solvent was removed and the residue was partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was further extracted with water (2 x 25 mL). The combined aqueous

layers were then extracted with CH₂Cl₂ (4 x 25 mL). The combined CH₂Cl₂ layers were dried over MgSO₄, and the solvent was removed under reduced pressure. The residue was triturated with CHCl₃-ethyl acetate (1:5). The imidazolium salt, ITBp·HCl (1.45 g, 20%), was obtained as an off-white solid. ¹H NMR (CD₂Cl₂, 400 MHz): δ 11.7-9.7 (broad s, 1H); 8.4-6.7 (broad s, 2H), 7.74 (m, 2H), 7.62 (td, *J* = 8.8, 1.6 Hz, 2H); 7.45 (td, *J* = 7.6, 1.2 Hz, 2H), 1.36 (s, 9H). ¹³C NMR (CD₂Cl₂, 100 MHz): δ 145.9 (broad), 140.9 (broad), 131.7, 129.1 (broad), 127.6, 125.6 (broad), 356.0, 31.8. Anal. Calcd. For C₂₃H₂₉ClN₃ (368.94): C, 74.88; H, 7.92; N, 7.59. Found: C, 75.05, 7.89, 7.72.

Example 2

FIG. 4A shows a schematic synthesis of IPr-Pd(dmmba)Cl (dmmba = *k*²*N*,*C*-*N*,*N*-dimethylbenzylamine), which was synthesized according to the following method. Finely powdered PdCl₂ (177 mg, 1.00 mmol) was suspended in CH₃CN (5 mL), and *N*-benzyltrimethylamine (160 μL, 143 mg, 1.05 mmol) were added. The solution was heated to 80°C with stirring until clear, orange solution was formed (approx. 20 min). Finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added and the stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IPr·HCl (467 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (3:1, vol/vol, 150 mL), and the solvents were evaporated. The products were triturated with hexanes (25 mL). After drying in high vacuum, IPr-Pd(dmmba)Cl (543 mg, 82%) was obtained as beige solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.40 (t, *J* = 7.6 Hz, 2H), 7.30 (d, *J* = 7.6 Hz, 2H); 7.21 (s, 2H), 6.82-6.70 (m, 3H), 6.53 (d, *J* = 7.6 Hz, 1H), 3.46 (s, 2H), 3.37 (m, 2H), 3.15 (m, 2H), 2.39 (s, 6H), 1.49 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.8 Hz, 6H), 1.02 (d, *J* = 6.8 Hz, 6H), 0.81 (d, *J* = 6.4 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 177.5, 150.5, 147.8, 147.8, 144.7, 136.2, 136.1, 129.7, 125.4, 124.6, 124.0, 123.8, 122.6, 121.5, 72.6, 49.8, 29.0, 28.3, 26.4, 26.2, 23.2, 23.2. Anal. calcd for C₃₆H₄₈ClN₃Pd (665.67): C, 65.05; H, 7.28; N, 6.32. Found: C, 65.14; H, 7.41; N, 6.53.

Example 3

FIG. 4B shows a schematic synthesis of IEt-Pd(dmmba)Cl, which was synthesized according to the following method. Finely powdered PdCl₂ (177 mg, 1.00 mmol) was suspended in CH₃CN (5 mL) and N-benzyltrimethylamine (160 μL, 1.05 mmol) were added. The solution was heated to 80°C with stirring until a clear, orange solution was formed (approx. 20 min). Finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added and the stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IEt·HCl (406 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (3:1, vol/vol, 150 mL), and the solvents were evaporated. The products triturated with hexanes (25 mL). After drying in high vacuum, IEt-Pd(dmmba)Cl (492 mg, 81%) was obtained as beige solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.30 (t, *J* = 7.6 Hz, 2H), 7.24 (dd, *J* = 7.6, 1.2 Hz, 2H), 7.16 (s, 2H), 7.04 (dd, *J* = 7.6, 1.2 Hz, 2H), 6.78 (td, *J* = 7.6, 1.2 Hz, 1H), 6.71 (d, *J* = 7.2, 1.0 Hz, 1H), 6.68 (td, *J* = 7.6, 1.2 Hz, 1H), 6.58 (d, *J* = 7.2, 1.0 Hz, 1H), 3.44 (s, 2H), 2.94 (m, 2H), 2.87 (m, 2H), 2.70 (m, 2H), 2.61 (m, 2H), 2.40 (s, 6H), 1.19 (t, *J* = 7.2 Hz, 6H), 1.18 (d, *J* = 7.6 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 175.7, 150.0, 147.2, 143.1, 137.0, 137.3, 137.1, 129.1, 126.3, 126.0, 124.0, 123.4, 122.7, 121.1, 72.3, 50.0, 29.0, 25.9, 25.2, 13.3, 14.7. Anal. calcd for C₃₂H₄₁ClN₃Pd (609.56): C, 63.16; H, 6.63; N, 6.90. Found: C, 63.69; H, 6.80; N, 7.03.

Example 4

FIG. 4C shows a schematic synthesis of IMes-Pd(dmmba)Cl, which was synthesized according to the following method. Finely powdered PdCl₂ (177 mg, 1.00 mmol) was suspended in CH₃CN (5 mL) and N-benzyltrimethylamine (160 μL, 1.05 mmol) were added. The solution was heated to 80°C with stirring until a clear, orange solution was formed (approx. 20 min). Finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added and the stirring was continued until palladacycle formation was

complete, as indicated by the formation of a canary yellow solution (5-10 min).
IMes·HCl (375 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 18h.
The reaction mixture was filtered and evaporated. The resulting product was purified by
column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8
5 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The
pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (3:1, vol/vol, 150 mL),
and the solvent was evaporated. The products were triturated with hexanes (25 mL).
After drying in high vacuum, IMes-Pd(dmba)Cl (555 mg, 96%) was obtained as beige
solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.10 (s, 2H), 6.99 (s, 2H), 6.83-6.76 (m, 4H), 6.70
10 (td, *J* = 7.6, 1.2 Hz, 1H), 6.58 (d, *J* = 7.2, 1.2 Hz, 1H), 3.53 (s, 2H), 2.45 (s, 6H), 2.44 (s,
6H), 2.29 (s, 6H), 2.23 (s, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 175.6, 149.3, 147.6,
138.3, 138.3, 137.4, 136.2, 133.9, 129.4, 128.7, 123.9, 123.2, 123.0, 121.2, 72.2, 50.0,
21.1, 20.2, 19.8. Anal. calcd for C₃₀H₃₇ClN₃Pd (581.51): C, 61.96; H, 6.41; N, 7.23.
Found: C, 62.02; H, 6.37; N, 7.40.

15

Example 5

FIG. 4D shows a schematic synthesis of ITbp-Pd(dmba)Cl, which was
synthesized according to the following method. Finely powdered PdCl₂ (177 mg, 1.00
mmol) was suspended in CH₃CN (5 mL) and N-benzyltrimethylamine (160 μL, 143 mg,
20 1.05 mmol) were added. The solution was heated to 80°C with stirring until a clear,
orange solution was formed (approx. 20 min). Finely powdered K₂CO₃ (691 mg, 5.00
mmol) was added and the stirring was continued until the palladacycle formation was
complete, as indicated by the formation of a canary yellow solution (5-10 min).
ITbp·HCl (406 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 18h.
25 The reaction mixture was filtered and evaporated. The resulting product was purified by
column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8
cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The
pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (3:1, vol/vol, 150 mL)
and the solvents were evaporated. The products were triturated with hexanes (25 mL).
30 After drying in high vacuum, ITbp-Pd(dmba)Cl (494 mg, 81%) was obtained as beige
solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.62 (dd, *J* = 8.4, 1.6 Hz, 2H), 7.42 (dd, *J* = 8.0,
1.2 Hz, 2H), 7.30-7.22 (m, 2H), 7.29 (s, 2H), 6.93-6.81 (m, 5H), 6.39 (d, *J* = 7.2 Hz),
3.51 (s, 2H), 2.42 (s, 6H), 1.51 (s, 18H). ¹³C NMR (CDCl₃, 100 MHz) δ: 176.7, 151.8,

148.0, 146.7, 137.6, 137.5, 131.8, 129.8, 128.7, 125.1, 125.1, 124.7, 123.0, 121.6, 72.4, 49.6, 36.7, 32.8. Anal. calcd for $C_{32}H_{41}ClN_3Pd$ (609.56): C, 63.05; H, 6.78; N, 6.89. Found: C, 63.69; H, 6.81; N, 7.11.

5

Example 6

FIG. 4E shows a schematic synthesis of SIPr-Pd(dmba)Cl (dmba = $k^2N,C-N,N$ -dimethylbenzylamine), which was synthesized according to the following method. Finely powdered $PdCl_2$ (177 mg, 1.00 mmol) was suspended in CH_3CN (5 mL) and N -benzyldimethylamine (160 μ L, 143 mg, 1.05 mmol) were added. The solution was
10 heated to 80°C with stirring until a clear, orange solution was formed (approx. 20 min). Finely powdered K_2CO_3 (691 mg, 5.00 mmol) was added and the stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). SIPr-HCl (469 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 48h. Alternatively, the mixture was heated at 100°C over 18h.
15 The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH_2Cl_2 , CH_2Cl_2 (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with CH_2Cl_2 -ethylacetate (3:1, vol/vol, 150 mL) and the solvents were evaporated. The products were triturated with hexanes (25 mL).
20 After drying in high vacuum, SIPr-Pd(dmba)Cl (328 mg, 49% at 80°C and 308 mg, 46% at 100°C) was obtained as beige solid. 1H NMR ($CDCl_3$, 400 MHz) δ : 7.36-7.28 (m, 4H), 7.22 (m, 1H); 7.10 (dd, J = 7.2, 1.6 Hz, 2H), 6.85 (m, 3H), 6.78 (m, 1H), 4.16 (m, 2H), 4.10 (m, 2H), 3.59 (m, 4H), 3.40 (s, 2H), 2.32 (s, 6H), 1.60 (d, J = 6.8 Hz, 6H), 1.26 (d, J = 6.8 Hz, 6H), 1.21 (d, J = 6.8 Hz, 6H), 0.74 (d, J = 6.8 Hz, 6H). ^{13}C NMR ($CDCl_3$, 100
25 MHz) δ : 205.4, 150.7, 148.0, 147.9, 146.3, 136.9, 136.0, 128.8, 125.3, 124.4, 124.0, 122.8, 121.7, 72.6, 54.2, 49.5, 29.0, 28.4, 27.0, 26.3, 24.3, 23.6. Anal. calcd for $C_{36}H_{50}ClN_3Pd$ (666.68): C, 64.86; H, 7.56; N, 6.30. Found: C, 65.19; H, 7.76; N, 6.39.

Example 7

30 FIG. 4F shows a schematic synthesis of IPr-PdCl-($k^2N,C-(S)$ - α -MeBnNMe₂), which was synthesized according to the following method. Finely powdered $(CH_3CN)_2PdCl_2$ (259 mg, 1.00 mmol) was suspended in CH_3CN (5 mL) and (S)- α,N,N -trimethylbenzylamine (173 μ L, 157 mg, 1.05 mmol) was added. The solution was

heated to 80°C for 5 min and finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added. The stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IPr·HCl (467 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (3:1, vol/vol, 150 mL), and the solvents were evaporated. The products were triturated with hexanes (25 mL). After drying in high vacuum, IPr-PdCl-(*k*²*N*,*C*-(*S*)-a-MeBnNMe₂) (542 mg, 80%) was obtained as beige solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.46 (t, *J* = 8.0 Hz, 2H), 7.34 (d, *J* = 4.4 Hz, 2H); 7.30-7.25 (m, 3H), 7.24 (d, *J* = 1.6 Hz, 1H); 7.19 (d, *J* = 1.6 Hz), 7.04 (m, 1H), 6.80 (td, *J* = 7.2, 1.2 Hz, 1H), 6.74 (m, 1H), 6.70 (dd, *J* = 7.2, 2.0 Hz, 1H), 6.55 (d, *J* = 6.8 Hz, 1H), 3.81 (m, 1H), 3.67 (m, 1H), 3.10 (q, *J* = 6.4 Hz, 1H), 2.92 (m, 1H), 2.45 (m, 1H), 2.37 (s, 3H), 2.27 (s, 3H), 1.52 (d, *J* = 6.8 Hz, 3H), 1.44 (d, *J* = 6.8 Hz, 3H), 1.20 (d, *J* = 6.8 Hz, 3H), 1.17 (d, *J* = 5.6 Hz, 3H), 1.15 (d, *J* = 5.6 Hz, 3H), 1.08 (d, *J* = 6.8 Hz, 3H), 0.96 (d, *J* = 6.4 Hz, 3H), 0.90 (d, *J* = 6.8 Hz, 3H), 0.46 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz) δ: 178.0, 154.5, 149.4, 147.9, 147.6, 144.8, 144.7, 136.5, 136.1, 136.0, 129.8, 129.5, 125.2, 125.2, 124.1, 123.8, 123.7, 122.7, 121.1, 75.3, 50.0, 46.6, 29.0, 29.0, 28.4, 28.2, 27.0, 26.8, 26.0, 25.3, 23.6, 23.4, 22.8, 22.6.

Example 8

FIG. 4G shows a schematic synthesis of IPr-PdCl-[*k*²*N*,*C*-3,5-(MeO)₂BnNMe₂], which was synthesized according to the following method. Finely powdered (CH₃CN)₂PdCl₂ (259 mg, 1.00 mmol) was suspended in CH₃CN (5 mL) and 3,5-dimethoxy-*N,N*-dimethylbenzylamine (205 mg, 1.05 mmol) was added. The solution was heated to 80°C for 5 min and finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added. The stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IPr·HCl (467 mg, 1.10 mmol) was added and the mixture stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles

were eluted with CH₂Cl₂-ethylacetate (3:1, vol/vol, 150 mL) and the solvents were evaporated. The products triturated with hexanes (25 mL). After drying in high vacuum, IPr-PdCl-[*k*²N,C-3,5-(MeO)₂BnNMe₂] (491 mg, 68%) was obtained as yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.39 (t, *J* = 7.6 Hz, 2H), 7.27 (dd, *J* = 7.6, 1.6 Hz, 2H), 7.18 (dd, *J* = 7.6, 1.2 Hz, 2H), 7.13 (s, 2H), 6.12 (d, *J* = 2.4 Hz, 3H), 5.99 (d, *J* = 2.4 Hz, 3H), 3.71 (s, 3H), 3.69 (m, 2H), 3.49 (s, 3H), 3.33 (s, 2H), 2.94 (m, 2H), 2.33 (s, 6H), 1.47 (d, *J* = 6.4 Hz, 6H), 1.18 (d, *J* = 6.8 Hz, 6H), 1.03 (d, *J* = 7.2 Hz, 6H), 0.99 (d, *J* = 6.4 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 175.5, 161.8, 157.4, 149.1, 148.2, 145.4, 136.8, 129.3, 127.9, 123.8, 123.7, 123.7, 99.9, 95.2, 73.4, 55.1, 54.9, 49.6, 29.0, 27.0, 26.6, 26.5, 24.2, 23.4.

Example 9

FIG. 4H shows a schematic synthesis of IPr-PdCl-[*k*²N,C-PhCH=NOH], which was synthesized according to the following method. Finely powdered (CH₃CN)₂PdCl₂ (259 mg, 1.00 mmol) was suspended in CH₃CN (5 mL) and (*E*)-benzaldehyde oxime (127 mg, 1.05 mmol) were added. The solution was heated to 80°C for 5 min and finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added and the stirring continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IPr·HCl (467 mg, 1.10 mmol) was added and the mixture stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (1:1, vol/vol, 150 mL) and the solvents were evaporated. The products were triturated with hexanes (25 mL). After drying in high vacuum, IPr-PdCl-[*k*²N,C-PhCH=NOH] (291 mg, 45%) was obtained as yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ: 7.40 (t, *J* = 8.0 Hz, 2H), 7.24 (dd, *J* = 8.0, 1.6 Hz, 2H), 7.18 (dd, *J* = 7.6, 1.2 Hz, 2H), 7.15 (s, 1H), 7.13 (s, 2H), 6.72 (dd, *J* = 7.2, 1.2 Hz, 1H), 6.68 (td, *J* = 8.4, 1.2 Hz, 1H), 6.46 (d, *J* = 6.4 Hz, 3H), 6.42 (td, *J* = 6.4, 1.6 Hz, 3H), 3.43 (s, 2H), 3.00 (s, 2H), 1.74 (broad s, 1H), 1.14 (d, *J* = 7.2 Hz, 6H), 1.11 (d, *J* = 6.8 Hz, 6H), 0.95 (d, *J* = 6.4 Hz, 6H), 0.90 (d, *J* = 6.8 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 182.0, 154.2, 152.0, 146.8, 146.0, 145.2, 137.0, 136.1, 129.3, 124.5, 123.9, 123.8, 123.2, 122.2, 121.0, 28.6, 28.0, 26.3, 26.0, 23.9, 22.4.

Example 10

FIG. 4I shows a schematic synthesis of IPr-PdCl-[*k*²*N*,*C*-2-PhPy], which was synthesized according to the following method. Finely powdered (CH₃CN)₂PdCl₂ (259 mg, 1.00 mmol) was suspended in CH₃CN (5 mL) and 2-phenylpyridine (150 μL, 163 mg, 1.05 mmol) was added. The solution was heated to 80°C for 5 min and finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added. The stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IPr·HCl (467 mg, 1.10 mmol) was added and the mixture was stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with CH₂Cl₂-ethylacetate (1:1, vol/vol, 150 mL) and the solvents were evaporated. The products were triturated with hexanes (25 mL). After drying in high vacuum, IPr-PdCl-[*k*²*N*,*C*-2-PhPy] (300 mg, 44%) was obtained as yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ: 9.30 (d, *J* = 0.8 Hz, 1H), 7.57 (td, *J* = 8.0, 1.6 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.38 (t, *J* = 8.0 Hz, 2H), 7.33 (dd, *J* = 8.0, 1.6 Hz, 2H), 7.30 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.28 (s, 2H), 7.18 (dd, *J* = 7.6, 1.6 Hz, 2H), 6.96 (td, *J* = 7.6, 1.2 Hz, 1H), 6.93 (dd, *J* = 7.6, 1.6 Hz, 1H), 6.89 (td, *J* = 7.6, 1.6 Hz, 3H), 6.73 (dd, *J* = 7.2, 0.8 Hz, 3H), 3.36 (m, 2H), 3.30 (m, 2H), 1.50 (d, *J* = 6.4 Hz, 6H), 1.18 (d, *J* = 6.8 Hz, 6H), 1.05 (d, *J* = 6.8 Hz, 6H), 0.80 (d, *J* = 6.8 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 178.8, 164.3, 155.7, 150.1, 147.8, 146.4, 145.0, 137.8, 137.5, 135.9, 129.9, 128.9, 125.0, 124.2, 124.0, 123.1, 122.8, 121.4, 117.4, 29.0, 28.5, 26.6, 26.2, 23.2, 22.0.

Example 11

FIG. 4J shows a schematic synthesis of IPr-PdCl-[*k*²*N*,*C*-2-PhPy], which was synthesized according to the following method. Finely powdered (CH₃CN)₂PdCl₂ (259 mg, 1.00 mmol) was suspended in CH₃CN (5 mL) and 2-benzylpyridine (170 μL, 178 mg, 1.05 mmol) was added. The solution was heated to 80°C for 5 min and finely powdered K₂CO₃ (691 mg, 5.00 mmol) was added. The stirring was continued until palladacycle formation was complete, as indicated by the formation of a canary yellow solution (5-10 min). IPr·HCl (467 mg, 1.10 mmol) was added and the mixture was

stirred at 80°C over 18h. The reaction mixture was filtered and evaporated. The resulting product was purified by column chromatography. Upon application of the product to a pad of silica gel (2.5 x 8 cm) pre-equilibrated with CH₂Cl₂, CH₂Cl₂ (100 mL) was used to elute impurities. The pure NHC-palladacycles were eluted with

5 CH₂Cl₂-ethylacetate (1:1, vol/vol, 150 mL) and the solvents were evaporated. The products triturated with hexanes (25 mL). After drying in high vacuum, IPr-PdCl-[*k*³N,C-2-PhPy] (464 mg, 66%) was obtained as yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ: 8.80 (d, *J* = 0.8 Hz, 1H), 7.56 (broad m, 1H), 7.42 (broad m, 4H), 7.20 (s, 2H), 7.07 (d, *J* = 7.6, 2H), 7.01 (broad m, 1H), 6.89 (t, *J* = 6.8 Hz, 1H), 6.74-6.68 (m, 3H), 6.61 (m, 1H),

10 3.79-3.76 (broad m, 2H), 3.37 (broad m, 3H), 2.37 (broad m, 1H), 1.64 (broad s, 3H), 1.54 (broad s 3H), 1.30 (broad s, 3H), 1.22 (broad s, 3H), 1.00 (broad s, 3H), 0.95 (broad s, 3H), 0.42 (broad s, 3H). ¹³C NMR (CDCl₃, 100 MHz) δ: 176.1, 159.4, 153.2, 150.1, 149.6, 148.2 (broad), 147.5 (broad), 145.4 (broad), 140.2, 137.3, 136.5 (broad), 136.0 (broad), 130.0 (broad), 129.4 (broad), 125.7, 125.2 (broad), 125.0, 124.6 (broad), 124.2

15 (broad), 123.6 (broad), 123.0 (broad), 122.3, 121.1, 49.2, 28.9, 28.8, 26.7, 26.3, 24.0, 23.2.

Example 12

The following example describes a general method for an anion exchange

20 reaction for compounds of the invention, as shown in FIG. 5. FIG. 6A shows a schematic synthesis of IPr-Pd(dmmba)OAc. To a suspension of AgOAc (167 mg, 1 mmol) in CH₂Cl₂ (2 mL), a solution of IPr-Pd(dmmba)Cl (665 mg, 1 mmol) in CH₂Cl₂ (3 mL) was added. The mixture was stirred over 1h and evaporated to dryness in the presence of silica gel (2 g). IPr-Pd(dmmba)OAc (663 mg, 96%) was obtained as a white solid after

25 chromatography (Combiflash, 12 g cartridge) with CH₂Cl₂-ethyl acetate : methanol (5:1, vol/vol) gradient, 0 to 100%. ¹H NMR (CDCl₃, 400 MHz) δ: 7.32 (t, *J* = 7.6 Hz, 2H), 7.22 (broad d, *J* = 7.6 Hz, 2H), 7.12 (s, 2H), 7.10 (broad d, *J* = 7.6 Hz, 2H), 6.68 (t, *J* = 7.2 Hz, 2H), 6.61 (m, 3H), 6.38 (d, *J* = 7.6 Hz, 1H), 3.24 (s, 2H), 3.20 (m, 2H), 2.81 (m, 2H), 2.18 (s, 6H), 1.40 (s, 3H), 1.33 (d, *J* = 6.4 Hz, 6H), 1.10 (d, *J* = 6.4 Hz, 6H), 0.93 (d,

30 *J* = 6.8 Hz, 6H), 0.79 (d, *J* = 6.4 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 178.3, 176.0, 148.2, 148.0, 147.0, 145.1, 136.0, 135.8, 129.6, 125.4, 124.2, 124.1, 123.8, 122.4, 121.7, 72.3, 49.2, 28.7, 28.5, 26.3, 25.3, 23.0, 22.8. Anal. calcd for C₃₈H₅₁N₃O₂Pd (688.25): C, 66.31; H, 7.47; N, 6.11. Found: C, 66.70; H, 7.63; N, 6.31.

Example 13

FIG. 6B shows a schematic synthesis of IPr-Pd(dmba)OCOCF₃. To a suspension of AgOCOCF₃ (221 mg, 1 mmol) in CH₂Cl₂ (2 mL), a solution of IPr-Pd(dmba)Cl (665 mg, 1 mmol) in CH₂Cl₂ (3 mL) was added. The mixture was stirred over 1h and evaporated to dryness in the presence of silica gel (2 g). IPr-Pd(dmba)OCOCF₃ (733 mg, 99%) was obtained as a white solid after chromatography (Combiflash, 12 g cartridge) with CH₂Cl₂ - ethyl acetate gradient, 0 to 100%. ¹H NMR (CDCl₃, 400 MHz) δ: 7.42 (t, *J* = 7.6 Hz, 2H), 7.30 (d, *J* = 7.6 Hz, 2H), 7.25 (s, 2H), 7.21 (d, *J* = 7.6 Hz, 2H), 6.80 (td, *J* = 6.8, 1.2 Hz, 2H), 6.70 (m, 2H), 6.70 (d, *J* = 7.6 Hz, 1H), 3.34 (s, 2H), 3.29 (m, 2H), 2.84 (m, 2H), 2.24 (s, 6H), 1.36 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.8 Hz, 6H), 1.03 (d, *J* = 6.8 Hz, 6H), 0.88 (d, *J* = 6.8 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz) δ: 177.3, 160.8 (q, ²*J*_{C-F} = 35 Hz), 147.6, 146.7, 145.9, 145.0, 136.0, 135.8, 135.4, 129.7, 125.7, 124.5, 124.3, 123.9, 122.7, 121.0, 160.8 116.6 (q, ¹*J*_{C-F} = 292 Hz), 72.0, 49.1, 28.6, 28.5, 26.3, 26.3, 23.0, 22.4. Anal. calcd for C₃₈H₄₈F₃N₃O₂Pd (742.22): C, 61.49; H, 6.52; N, 5.66. Found: C, 62.06; H, 6.67; N, 5.77.

Example 14

The following example describes the use of pre-catalysts of the invention in Suzuki-Miyaura cross-coupling reactions.

FIG. 7A shows the schematic synthesis of the Suzuki-Miyaura cross-coupling between 2-chloro-1,3-xylene and 1-naphthylboronic acid, using a weak base. In a tube with a stirbar, 1-naphthylboronic acid (722 mg, 4.2 mmol), Cs₂CO₃ (1.95g, 6.0 mmol) and IPr-Pd(dmba)Cl (27 mg, 0.040 mmol) were sealed with a septum and the tube was backfilled with Ar (3 ×). Dry DMF (12 mL) was added to the tube and the mixture was heated to 120°C. 2-Chloro-1,3-xylene (530 μL, 562 mg, 4.0 mmol) was added dropwise. The reaction was heated overnight, cooled, and partitioned between ether (20 mL) and water (20 mL). The ether layer was washed with water (4 × 20 mL), dried (MgSO₄) and evaporated. The product (359 mg, 39%) was obtained as waxy white solid after column chromatography on silica gel, using hexanes as the eluent. The ¹H- and ¹³C NMR spectra were identical as described in literature (for example, as described in Navarro, O.; Kelly, R. A., III; Nolan, S. P. *J. Am. Chem. Soc.* **2003**, *125*, 16194-16195).

FIG. 7B shows the schematic synthesis of the Suzuki-Miyaura cross-coupling between 2-chloro-1,3-xylene and 1-naphthylboronic acid, using a strong base. In a tube with a stirbar, 1-naphthylboronic acid (1.35 g, 7.9 mmol), and *t*-BuONa (793 mg, 8.3 mmol) were sealed with a septum, and the tube was backfilled with Ar (3 ×). 2-Chloro-1,3-xylene (1.00 mL, 1.06 g, 7.5 mmol) was added. A solution containing IPr-Pd(dmba)Cl (50 mg, 0.075 mmol) in *i*-PrOH (reagent grade, 8 mL) was injected and the catalyst was activated by heating with heat gun. The reaction was stirred at room temperature overnight, the solvent removed and the residue partitioned between CH₂Cl₂ (30 mL) and water (50 mL). The organic layer was separated, dried (MgSO₄) and evaporated. As described above, the product (1.31 g, 75%) was obtained as waxy white solid after column chromatography on silica gel, using hexanes as the eluent.

Example 15

The following example describes the use of a pre-catalyst of the invention in a Buchwald-Hartwig amination reaction.

FIG. 7C shows the schematic synthesis of the Buchwald-Hartwig amination of 2-chloro-1,3-xylene with 2,6-diisopropylaniline. A vial with a stirbar was charged with *t*-BuONa (173 mg, 1.8 mmol). A solution containing IPr-Pd(dmba)Cl (13.3 mg, 0.020 mmol) in toluene (reagent grade; 2 mL) was added to the vial. 2-Chloro-1,3-xylene (135 μL, 141 mg, 1.0 mmol) and 2,6-diisopropylaniline (225 μL, 212 mg, 1.2 mmol) were added in succession. The atmosphere above the vial was purged with a stream of Ar, and the vial was capped, sealed, and heated at 120°C over 18h. The crude reaction mixture was transferred into a round-bottomed flask, and the volatile solvents were removed. The remaining residue was purified by column chromatography on silica gel (Combiflash 12 g cartridge, hexane over 5 min, then hexane-ethyl acetate 0 to 100% gradient over 15 min). The product (167 mg, 59%) was obtained as colorless oil. The ¹H- and ¹³C NMR were identical as described in the literature (for example, as described in Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. *J. Org. Chem.* **2000**, *65*, 1158-1174).

Example 16

The following example describes the use of a pre-catalyst of the invention in a Heck-Mizoroki cross-coupling reaction.

FIG. 7D shows the schematic synthesis of the Heck-Mizoroki reaction between 4-bromo-2,6-dimethylaniline and tert-butyl acrylate. A vial was charged with a stirbar, 4-bromo-2,6-dimethylaniline (200 mg, 1.0 mmol), K₂CO₃ (276 mg, 2.0 mmol) and IPr-Pd(dmba)Cl (13.3 mg, 0.020 mmol). The vial was backfilled with Ar (3 ×), and NMP (purged with Ar; 2 mL) and tert-butyl acrylate (175 μL, 154 mg, 1.2 mmol) were added via syringe. The mixture was heated to 140°C overnight, cooled, and partitioned between ether (20 mL) and water (20 mL). The ether layer was washed with water (2 × 20 mL) and dried (MgSO₄), and the solvent was evaporated. The product (225 mg, 91%) was obtained as pale yellow oil after purification by column chromatography on silica gel (Combiflash 12 g cartridge, hexane-ethyl acetate 0 to 10% gradient over 20 min). ¹H NMR (CDCl₃, 400 MHz) δ: 7.48 (d, *J* = 16.0 Hz, 1H), 7.15 (s, 2H), 6.19 (d, *J* = 16.0 Hz, 1H), 2.19 (s, 6H), 1.53 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz) δ: 167.2, 145.0, 144.3, 128.6, 124.3, 121.5, 115.3, 79.8, 28.3, 17.6. Using a similar procedure (NMP, volume 0.4 mL), the product (88%, 217 mg) was obtained with IMes-Pd(dmba)Cl (11.6 mg, 0.020 mmol) as an alternative precatalyst,

Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are listed here.

The term “catalytic amount” is recognized in the art and refers to a substoichiometric amount relative to a reactant.

The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups, all optionally substituted. In some embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C₁-C₃₀ for straight chain, C₃-C₃₀ for branched chain), and, in some cases, 20 or fewer.

The term “heteroalkyl” refers to an alkyl group as described herein in which one or more carbon atoms is replaced by a heteroatom. Suitable heteroatoms include oxygen, sulfur, nitrogen, phosphorus, and the like. The term “cycloheteroalkyl” refers to cycloalkyl groups in which one or more carbon atoms is replaced by a heteroatom.

The term “aryl” refers to aromatic carbocyclic groups, optionally substituted, having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed

rings in which at least one is aromatic (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl). That is, at least one ring may have a conjugated pi electron system. The aryl group may be optionally substituted, as described herein. "Carbocyclic aryl groups" refer to aryl groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and polycyclic or fused compounds such as naphthyl groups.

"Heterocyclic aryl" or "heteroaryl" groups are aryl groups wherein at least one ring atom in the aromatic ring is a heteroatom, and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, nitrogen, phosphorus, and the like. Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, indolyl and the like, all optionally substituted.

The term "aralkyl" refers to an alkylene group substituted with an aryl group. Suitable aralkyl groups may include benzyl, picolyl, and the like, and may be optionally substituted. The aryl portion may have 5-14 ring atoms and the alkyl portion may have up to and including 10 carbon atoms. "Heteroarylalkyl" refers to an alkylene group substituted with a heteroaryl group.

The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula: N(R')(R'')(R''') wherein R', R'', and R''' each independently represent a group permitted by the rules of valence.

The terms triflyl, tosyl, mesyl, and nonaflyl are art-recognized and refer to trifluoromethanesulfonyl, p-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl groups, respectively. The terms triflate, tosylate, mesylate, and nonaflate are art-recognized and refer to trifluoromethanesulfonate, p-toluenesulfonate, methanesulfonate, and nonafluorobutanesulfonate functional groups and molecules that contain said groups in either neutral (e.g., ester) form or ionic (e.g., salt) form, respectively.

The term "carbonyl" is recognized in the art and refers to the group, C=O.

The terms "carboxyl group," "carbonyl group," and "acyl group" are recognized in the art and can include such moieties as can be represented by the general formula:



wherein W is H, OH, O-alkyl, O-alkenyl, or a salt thereof. Where W is O-alkyl, the formula represents an "ester." Where W is OH, the formula represents a "carboxylic acid." The term "carboxylate" refers to an anionic carboxyl group. In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a
5 "thiolcarbonyl" group. Where W is a S-alkyl, the formula represents a "thiolester." Where W is SH, the formula represents a "thiolcarboxylic acid." On the other hand, where W is alkyl, the above formula represents a "ketone" group. Where W is hydrogen, the above formula represents an "aldehyde" group.

The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous
10 in length and possible substitution to the alkyls described above, but which contain at least one double or triple carbon-carbon bond, respectively. The term "alkenylalkyl" refers to an alkyl groups substituted with an alkenyl group. The term "alkynylalkyl" refers to an alkyl groups substituted with an alkynyl group.

The term "alkoxy-" or "alkyloxy-" refers to the group O-alkyl.

15 The term "halide" refers to -F, -Cl, -Br, or -I.

The term "sulfonate" is given its ordinary meaning in the art and refers to the group, $\text{SO}_3\text{W}'$, where W' may be an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.

As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds, "permissible" being in the context of the chemical
20 rules of valence known to those of ordinary skill in the art. In some cases, "substituted" may generally refer to replacement of a hydrogen with a substituent as described herein. However, "substituted," as used herein, does not encompass replacement and/or alteration of a key functional group by which a molecule is identified, e.g., such that the "substituted" functional group becomes, through substitution, a different functional
25 group. For example, a "substituted aldehyde" must still comprise the aldehyde moiety and can not be modified by substitution, in this definition, to become, e.g., a carboxylic acid. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described
30 herein. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. This

invention is not intended to be limited in any manner by the permissible substituents of organic compounds.

Examples of substituents include, but are not limited to, alkyl, aryl, aralkyl, cyclic alkyl, heterocycloalkyl, hydroxy, alkoxy, aryloxy, perhaloalkoxy, aralkoxy, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroaralkoxy, azido, amino, halide, alkylthio, oxo, acylalkyl, carboxy esters, carboxyl, -carboxamido, nitro, acyloxy, aminoalkyl, alkylaminoaryl, alkylaryl, alkylaminoalkyl, alkoxyaryl, arylamino, aralkylamino, alkylsulfonyl, -carboxamidoalkylaryl, -carboxamidoaryl, hydroxyalkyl, haloalkyl, alkylaminoalkylcarboxy-, aminocarboxamidoalkyl-, cyano, alkoxyalkyl, perhaloalkyl, arylalkyloxyalkyl, and the like.

While several embodiments of the present invention have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present invention is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the invention may be practiced otherwise than as specifically described and claimed. The present invention is directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of the present invention.

The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one."

The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.


As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally

including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

- 5 In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States
- 10 Patent Office Manual of Patent Examining Procedures, Section 2111.03.


What is claimed:

1. A method for synthesizing a transition metal-containing precatalyst, comprising:
reacting at least three components all contained together in a single reaction chamber to form a transition metal-containing precatalyst having one of the following structures,



wherein M is Pd, Pt, or Ru; each R¹⁻⁸ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁸ are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a heteroatom; C is alkyl or aryl; D is a heteroatom; X¹ is halide, sulfonate, or carboxylate; X² is a neutral ligand; Y is a counterion;  is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof; --- is a single bond or double bond; and n is an integer between 1 and 3; and

wherein the transition metal-containing precatalyst does not have the following structure,




2. A method as in claim 1, wherein each R¹⁻⁸ is independently hydrogen, alkyl, cycloalkyl, alkoxy, amino, aryl, heteroaryl, or substituted derivatives thereof; A is carbon, nitrogen, phosphorus, oxygen, or sulfur; C is nitrogen, phosphorus, oxygen, or sulfur; D is nitrogen, phosphorus, arsenic, antimony, oxygen, sulfur, selenium, or tellurium; and n is an integer between 1 and 3.


3. A method as in claim 1, wherein A and B are nitrogen; D is nitrogen, phosphorus, or sulfur; R¹ and R² are aromatic rings optionally substituted with methyl, ethyl, isopropyl, t-butyl, methoxy, isopropoxy, trifluoromethyl, or phenyl; R³ and R⁴ are phenyl, t-butyl, or are joined together to form a six-membered ring; R⁵ and R⁶ are hydrogen, t-butyl, methoxy, trifluoromethyl, or are joined together to form an aryl ring; R⁷ and R⁸ are methyl, isopropyl, t-butyl, phenyl, phenoxy, hydroxyl, R⁷ and R⁸ are joined together to form a ring; or at least one of R⁷ and R⁸ is joined to a portion of  to form a ring.

4. A method as in claim 1, wherein M is Pd, R¹ and R² are aromatic rings substituted with methyl, ethyl, isopropyl, tert-butyl or combinations thereof, A and C are nitrogen, and D is nitrogen or phosphorus.

5. A method as in claim 1, wherein the transition metal-containing precatalyst has the following structure,




6. A method as in claim 1, wherein the transition metal-containing precatalyst has the following structure,



7. A method as in claim 1, wherein the counterion is BF₄, PF₆, or Ar₄B, wherein Ar is aryl.


8. A method as in claim 1, wherein the neutral ligand comprises a nitrile, ether, or alcohol.

9. A method as in claim 1, wherein the neutral ligand is acetonitrile, tetrahydrofuran, or methanol.
10. A method as in claim 1, wherein the transition metal-containing precatalyst is stable in the presence of oxygen.
11. A method as in claim 1, wherein the transition metal-containing precatalyst is stable in the presence of water.
12. A method as in claim 1, wherein one of the three components is a palladium-containing compound.
13. A method as in claim 1, wherein the palladium-containing compound is PdCl₂.
14. A method as in claim 1, wherein the palladium-containing compound is (CH₃CN)₂PdCl₂.
15. A method as in claim 1, wherein one of the three components is an N-heterocyclic carbene ligand precursor.
16. A method as in claim 1, wherein the N-heterocyclic carbene ligand precursor has the structure,




each R¹⁻⁴ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁴ are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a heteroatom; --- is a single bond or double bond; n is an integer between 1 and 3; and Z is halide, sulfonate, carboxylate, BF₄, PF₆, or Ar₄B, wherein Ar is aryl.


17. A method as in claim 16, wherein the N-heterocyclic carbene ligand precursor has the structure,



18. A method as in claim 16, wherein the N-heterocyclic carbene ligand precursor has the structure,



19. A method as in claim 1, wherein one of the three components is a compound having the structure,



wherein each R^{5-8} is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R^{5-8} are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; C is alkyl or aryl; D is a heteroatom; X is halide or carboxylate;  is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof.

20. A method as in claim 1, further comprising a base.


21. A method as in claim 20, wherein the base is an inorganic base.

22. A method as in claim 20, wherein the base is a carbonate, phosphate, halide, or hydride.

23. A method as in claim 20, wherein the base is potassium carbonate, cesium carbonate, sodium carbonate.


24. A method as in claim 20, wherein the base is K_2CO_3 .

25. A method as in claim 1, further comprising a solvent.
26. A method as in claim 25, wherein the solvent is a polar solvent.
27. A method as in claim 25, wherein the solvent is acetonitrile, acetone, methanol, ethanol, propanol, butanol, ethylene glycol dimethyl ether, dimethylformamide, tetrahydrofuran, dimethylsulfoxide.
28. A method as in claim 25, wherein the solvent is a acetonitrile.
29. A method as in claim 1, further comprising an inorganic salt.
30. A method as in claim 1, wherein the at least three components are a palladium-containing compound, an N-heterocyclic carbene ligand precursor, and a compound having the structure,




wherein each R^{5-8} is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R^{5-8} are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; C is alkyl or aryl; D is a heteroatom; X is halide, sulfonate, or carboxylate; --- is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof.

31. A method as in claim 1, wherein the at least three components are not joined by a bond prior to the reacting.
32. A method as in claim 1, wherein the method is represented by Scheme 1,




Scheme 1


33. A composition of matter, comprising a compound having one of the following structures,



wherein M is Pd, Pt, or Ru; each R¹⁻⁸ is independently absent, hydrogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or a substituted derivative thereof, or wherein any two of R¹⁻⁸ are joined to form a cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, or substituted derivative thereof; A is carbon or a heteroatom; B is a heteroatom; C is alkyl or aryl; D is a heteroatom; X¹ is halide, sulfonate, or carboxylate; X² is a neutral ligand; Y is a counterion; — is alkyl, heteroalkyl, aryl, heteroaryl, or a substituted derivative thereof; — is a single bond or double bond; and n is an integer between 1 and 3;

wherein the compound does not have the following structure,






34. A composition as in claim 33, wherein each R^{1-8} is independently hydrogen, alkyl, cycloalkyl, alkoxy, amino, aryl, heteroaryl, or substituted derivatives thereof; A is carbon, nitrogen, phosphorus, oxygen, or sulfur; B is nitrogen, phosphorus, oxygen, or sulfur; D is nitrogen, phosphorus, arsenic, antimony, oxygen, sulfur, selenium, or tellurium; and n is an integer between 1 and 3.

35. A composition as in claim 33, wherein A and B are nitrogen; D is nitrogen, phosphorus, or sulfur; R^1 and R^2 are aromatic rings optionally substituted with methyl, ethyl, isopropyl, t-butyl, methoxy, isopropoxy, trifluoromethyl, or phenyl; R^3 and R^4 are phenyl, t-butyl, or are joined together to form a six-membered ring; R^5 and R^6 are hydrogen, t-butyl, methoxy, trifluoromethyl, or are joined together to form an aryl ring; R^7 and R^8 are methyl, isopropyl, t-butyl, phenyl, phenoxy, hydroxyl, R^7 and R^8 are


joined together to form a ring; or at least one of R^7 and R^8 is joined to a portion of  to form a ring.

36. A composition as in claim 33, wherein M is Pd, R^1 and R^2 are aromatic rings substituted with methyl, isopropyl, or combinations thereof, A and B are nitrogen, and D is nitrogen or phosphorus.


37. A composition as in claim 33, wherein the compound has the following structure,




38. A composition as in claim 33, wherein the compound has the following structure,




39. A composition as in claim 33, wherein the compound has the following structure,




40. A composition as in claim 33, wherein the compound has the following structure,




41. A composition as in claim 33, wherein the compound has the following structure,




42. A composition as in claim 33, wherein the compound has the following structure,




43. A composition as in claim 33, wherein the compound has the following structure,




44. A composition as in claim 33, wherein the compound has the following structure,



45. A composition as in claim 33, wherein the compound has the following structure,



46. A composition as in claim 33, wherein the compound has the following structure,



47. A composition as in claim 33, wherein the counterion is BF_4 , PF_6 , or Ar_4B , wherein Ar is aryl.


48. A composition as in claim 33, wherein the neutral ligand comprises a nitrile, ether, or alcohol.

49. A composition as in claim 33, wherein the neutral ligand is acetonitrile, tetrahydrofuran, or methanol.

50. A composition as in claim 33, wherein the compound is stable in the presence of oxygen.


51. A composition as in claim 33, wherein the compound is stable in the presence of water.

52. A composition of matter, comprising a compound having the following structure,



wherein $\equiv$ is a single bond or double bond.

53. A composition of matter, comprising a compound having the following structure,



wherein $\equiv$ is a single bond or double bond.